Multiple Sclerosis Patients have an Altered Gut Mycobiome and Increased Fungal to Bacterial Richness

Abstract

Trillions of microbes such as bacteria, fungi, and viruses exist in the healthy human gut microbiome. Although gut bacterial dysbiosis has been extensively studied in multiple sclerosis (MS), the significance of the fungal microbiome (mycobiome) is an understudied and neglected part of the intestinal microbiome in MS. The aim of this study was to characterize the gut mycobiome of patients with relapsing-remitting multiple sclerosis (RRMS), compare it to healthy controls, and examine its association with changes in the bacterial microbiome. We characterized and compared the mycobiome of 20 RRMS patients and 33 healthy controls (HC) using Internal Transcribed Spacer 2 (ITS2) and compared mycobiome interactions with the bacterial microbiome using 16S rRNA sequencing. Our results demonstrate an altered mycobiome in RRMS patients compared with HC. RRMS patients showed an increased abundance of Basidiomycota and decreased Ascomycota at the phylum level with an increased abundance of Candida and Epicoccum genera along with a decreased abundance of Saccharomyces compared to HC. We also observed an increased ITS2/16S ratio, altered fungal and bacterial associations, and altered fungal functional profiles in MS patients compared to HC. This study demonstrates that RRMS patients had a distinct mycobiome with associated changes in the bacterial microbiome compared to HC. There is an increased fungal to bacterial ratio as well as more diverse fungal-bacterial interactions in RRMS patients compared to HC. Our study is the first step towards future studies in delineating the mechanisms through which the fungal microbiome can influence MS disease.

Identification and characterization of four bacteriome- and mycobiome-derived subtypes in tumour and adjacent mucosa tissue of colorectal cancer patients

“…Nevertheless, we observed a robust shift in fungal composition, namely an enrichment of Basidiomycota and depletion of Ascomycota, when transitioning from on-tumour to off-tumour adjacent mucosa. A higher Basidiomycota:Ascomycota ratio has been reported as indicative of fungal dysbiosis in CRC [14][15][16], other cancers [46] and autoimmune diseases [47][48][49]. The higher Basidiomycota RA observed on-tumour stemmed from Malasseziaceae, which has been linked to CRC, other gastrointestinal cancers [46,50], multiple inflammatory [51,52] and skin disorders [53].…”